3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
2
palbociclib
2
cediranib
2
Radiotherapy
2
Methods
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
osimertinib
1
omipalisib
1
nanocis
1
montanide ISA 51
1
larotrectinib
1
ipatasertib
1
erythromycin propionate-N-acetylcysteinate
1
erdafitinib
1
entinostat
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
brodalumab
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled